Indapamide and bendrofluazide: a comparison in the management of essential hypertension
- PMID: 7041937
- PMCID: PMC1401924
- DOI: 10.1111/j.1365-2125.1981.tb01325.x
Indapamide and bendrofluazide: a comparison in the management of essential hypertension
Abstract
1 To compare the efficacy of indapamide with that of bendrofluazide a randomised trial was carried out in twenty patients with essential hypertension. 2 Indapamide (2.5 mg a day) and bendrofluazide (5 mg a day) produced a significant but equivalent fall in blood pressure. 3 Both drugs caused a reduction in body weight and serum potassium with a rise in plasma renin activity but there were no other major side effects. 4 In twelve patients treated with a combination of indapamide and bendrofluazide there was no additional fall in mean blood pressure or serum potassium compared to treatment with bendrofluazide or indapamide alone.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
